Siemens Healthineers Shareholders Get Two Bullish Calls—and a Long Wait for Accela Revenue
Published on 10/05/2026 at 00:50 | Editorial boerse-global.de
Siemens Healthineers wrapped up the trading week on a firmer note, with the stock closing Friday at EUR 37.92 on Xetra, a gain of 1.1 percent. That single-session advance does little to mask the broader picture: since the start of the year, the medical technology group's shares have shed 16 percent.
Analysts, though, are not short on conviction. David Adlington of JPMorgan reiterated his "Overweight" rating on Tuesday, setting a price target of EUR 57.40. A day later, Jefferies analyst Julien Dormois reaffirmed his own buy recommendation with a EUR 50 target. Both calls lean heavily on the same catalyst—Accela, the radiotherapy platform Siemens Healthineers unveiled on September 27 at the ASTRO congress in Boston.
Built on NeoArc technology, Accela is designed to deliver multi-target stereotactic irradiation in 60 seconds and to complete treatment within a single breath-hold cycle. Dormois went so far as to call it a quantum leap in radiation therapy. JPMorgan's Adlington sees the efficiency gain as a potential operational share-price driver down the road.
Clearance Still Pending, Revenue Years Away
The enthusiasm comes with a caveat that neither analyst glosses over. Accela is not yet available for sale in any market. In the United States, the 510(k) clearance from the FDA has yet to be granted. Jefferies expects meaningful revenue only in 2027/2028, once the necessary approval procedures, device installations, and production ramp-up are complete.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Since the platform's introduction just over a week ago, the stock has slipped 2.7 percent—a reminder that the market is pricing in the wait, not just the promise.
Partnerships and Diagnostics Fill the Gap
While Accela moves through the regulatory pipeline, Siemens Healthineers is broadening its commercial footprint elsewhere. On September 26, the company struck a distribution partnership with Mureva Phototherapy for the US market, covering the joint marketing of an intraoral system for treating radiation-induced oral mucositis. Two days later, it showcased new diagnostic and monitoring solutions at a laboratory medicine congress in Hamburg.
Existing hardware is also generating clinical momentum. At the Rhön-Klinikum Campus Bad Neustadt, the Naeotom Alpha.Peak system is being used in neuroradiology for high-resolution imaging of neurovascular structures, including vascular stenoses and aneurysms.
Buyback Keeps Rolling
Behind these commercial moves, the company continues to repurchase its own shares. According to mandatory disclosures, Siemens Healthineers acquired 160,000 shares between September 21 and 27, as reported in the 17th interim notification on September 28. Since the program began on June 1, the total volume has reached 3,374,359 shares.
Such purchases lend support to the market and help underpin the capital structure, though they have only partially offset the weaker year-to-date performance.
November 5 Looms Large
The fourth quarter of fiscal year 2026 ended on September 30. Management confirmed in a Tuesday conference call that no preliminary figures would be released ahead of the reporting date. Investors will get the full results on November 5, when the company presents its quarterly numbers at an analyst conference—the next scheduled milestone in a year that has so far rewarded patience more than conviction.
Ad
Siemens Healthineers Stock: New Analysis - 5 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
